Answers are grounded in this paper and cite their sources.
Background: To describe the real-world safety, steroid-sparing effect, treatment duration, infusion interval, and operational features of a medical ophthalmology-led biologic service managing non-infectious uveitis(NIU) patients with infliximab(IFX). Methods: Retrospective cohort review of patients receiving IFX for NIU at a tertiary NHS centre from March 2016 to March 2026. Primary outcomes were adverse events(AEs), serious adverse events(SAEs) and discontinuations; secondary outcomes were oral corticosteroid requirement and visual acuity. Results: 44 patients contributed 1208 months of IFX exposure (100.7 patient-years), with a median of 21.5 months(IQR 9.5–32.0). 37/44 (84%) had previously received adalimumab. AEs were reported by 20/44 (45%), including infections in 10/44 (23%) and rash in 9/44 (20%). SAEs occurred in 2/44 (5%): incident heart failure and anaphylaxis, each in 1/44 (2%). AEs led to discontinuation in 8/44 (18%). By 12 months, 10/44 (23%) had stopped IFX, most commonly due to ineffectiveness. Worse eye visual acuity changed by <15 ETDRS letters from baseline in 29/33 (88%), improved by ≥15 letters in 3/33 (9%), and worsened by ≥15 in 1/33 (3%). Among those using prednisolone at baseline, the median daily dose fell from 15 mg to 5.5 mg by month 12; at latest review (median 27 months) the median was 4.0 mg/day, with 18/21 (86%) taking ≤5 mg/day and 5/21 (24%) steroid-free. Conclusions: IFX was generally well tolerated and was associated with lower corticosteroid requirements in NIU. A medical ophthalmology-led biologic infusion service is feasible and safe but close collaboration with other medical specialties is critical for safe governance and delivery.
No takes yet. Share an insight, caveat, or question.
Braithwaite et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: